Evidence map›Paper›PMID 29706657›Full record

ArticleOncogene2018

Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.

Simon Sirtl, Gertrud Knoll, Dieu Thuy Trinh, Isabell Lang, Daniela Siegmund, Stefanie Gross, Beatrice Schuler-Thurner, Patrick Neubert, Jonathan Jantsch, Harald Wajant and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Simon SirtlInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany.
Gertrud KnollInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany.
Dieu Thuy TrinhInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany.
Isabell LangDivision of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University Hospital Würzburg, Röntgenring 11, Würzburg, 97070, Germany.
Daniela SiegmundDivision of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University Hospital Würzburg, Röntgenring 11, Würzburg, 97070, Germany.
Stefanie GrossDepartment of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Ulmenweg 18, Erlangen, 91054, Germany.
Beatrice Schuler-ThurnerDepartment of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Ulmenweg 18, Erlangen, 91054, Germany.
Patrick NeubertInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany.
Jonathan JantschInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany.
Harald WajantDivision of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University Hospital Würzburg, Röntgenring 11, Würzburg, 97070, Germany.
Martin EhrenschwenderInstitute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, 93053, Germany. martin.ehrenschwender@ukr.de.ORCID http://orcid.org/0000-0003-4681-8628
University Hospital Regensburg · DEUniversitätsklinikum Würzburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Attempts to exploit the cytotoxic activity of death receptors (DR) for treating cancer have thus far been disappointing. DR activation in most malignant cells fails to trigger cell death and may even promote tumor growth by activating cell death-independent DR-associated signaling pathways. Overcoming apoptosis resistance is consequently a prerequisite for successful clinical exploitation of DR stimulation. Here we show that hyperosmotic stress in the tumor microenvironment unleashes the deadly potential of DRs by enforcing BCL-2 addiction of cancer cells. Hypertonicity robustly enhanced cytotoxicity of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and other DR ligands in various cancer entities. Initial events in TRAIL DR signaling remained unaffected, but hypertonic conditions unlocked activation of the mitochondrial death pathway and thus amplified the apoptotic signal. Mechanistically, we demonstrate that hyperosmotic stress imposed a BCL-2-addiction on cancer cells to safeguard the integrity of the outer mitochondrial membrane (OMM), essentially exhausting the protective capacity of BCL-2-like pro-survival proteins. Deprivation of these mitochondrial safeguards licensed DR-generated truncated BH3-interacting domain death agonist (tBID) to activate BCL-2-associated X protein (BAX) and initiated mitochondrial outer membrane permeabilization (MOMP). Our work highlights that hyperosmotic stress in the tumor environment primes mitochondria for death and lowers the threshold for DR-induced apoptosis. Beyond TRAIL-based therapies, our findings could help to strengthen the efficacy of other apoptosis-inducing cancer treatment regimens.

Indexed as

ApoptosisApoptosis Regulatory Proteinsbcl-2-Associated X ProteinCell DeathCell Line, TumorHCT116 CellsHEK293 CellsHT29 CellsHumansMitochondriaMitochondrial MembranesMitochondrial ProteinsOsmotic PressureProto-Oncogene Proteins c-bcl-2Receptors, Death DomainReceptors, TNF-Related Apoptosis-Inducing LigandApoptosis Regulatory Proteinsbcl-2-Associated X ProteinBCL2 protein, humanMitochondrial ProteinsProto-Oncogene Proteins c-bcl-2Receptors, Death DomainReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID29706657
PMCPMC6062497
OpenAlexW2800763849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.